

**Original article****The effectiveness of deferasirox to prevent from the occurrence of liver fibrosis in balb/c mice with iron overload**Hadi Sarosa<sup>1\*</sup>, Wildan Chanieful Wajjih<sup>2</sup>, Ulfah Dian Indrayani<sup>3</sup>**Abstract**

**Background:** Oxidation of hepatocyte mitochondria due to iron overload led to hepatocyte injury, elevated Transforming growth factor-  $\beta$  (TGF-  $\beta$ ), and fibrosis. Fibrosis starts with stellate cell fibrogenesis activated by chronic hepatocyte injury. Liver fibrosis is the main cause of morbidity and mortality in iron overload. Deferasirox is an iron chelation drug serving to bind iron overload and have an antifibrotic effect. **Aim:** To examine the effect of deferasirox on liver fibrosis prevention due to *iron overload*. **Methods:** This experimental research used a post-test only control group design on male Balb/c mice that were randomly divided into 3 groups, each n=5. Group 1 (NaCl+S) was administered with 0.3 cc Na Cl 0.9% through intra peritoneal (I.P) injection and drug solvent (Aquabidest, CMC and Nipagin) per oral (P.O) intermittently. Group 2 (Fe+S) was administered with 0.3 cc 1.5 mg Fe+sucrose (Venofer®) through I.P injection and drug solvent (Aquabidest, CMC and Nipagin) P.O intermittently. Group 3 (Fe+Dfx) 0.3 cc 1.5 mg Fe+sucrose (Venofer®) I.P injection, and deferasirox 20 mg/kgBW/day P.O intermittently. All of the treatments were given for 60 days. The fibrosis area fraction of the liver was assessed using *software ImageJ*. **Results:** The average fibrosis area fraction of group 1 was  $0.00 \pm 0.00\%$ , group 2 was  $9.17 \pm 8.54\%$  and group 3 was  $1.38 \pm 0.20\%$ . The fibrosis area fractions between groups 2 and 3 were significantly different with p value 0.000 ( $p < 0.05$ ). The body weight of group 2 was higher than that of groups 3 and 1.

**Conclusions:** Iron overload causes liver fibrosis in male Balb/c mice. Deferasirox administration may lower the area of liver fibrosis in male Balb/c mice due to iron overload.

**Keywords:** Deferasirox; Iron chelation; Iron overload; TGF  $\beta$ ; and Liver fibrosis.

Bangladesh Journal of Medical Science Vol. 22 No. 01 January'23 Page : 84-90  
DOI: <https://doi.org/10.3329/bjms.v22i1.61865>

**Introduction**

Iron is an important micronutrient for humans, but excessive iron content may increase oxidative stress and tissue damage due to lipid peroxidation<sup>12</sup>. Excessive iron content in plasma will accumulate in the liver and other organs<sup>3,4</sup>. Iron overload is the main cause of chronic liver disease, besides fatty liver<sup>5</sup>. Accumulated iron in the liver may cause chronic inflammation that later causes fibrosis, cirrhosis and even malignancy of the liver<sup>6</sup>.

According to the World Health Organization (WHO) in 2019 hepatic cirrhosis was the 10<sup>th</sup> cause of death in low-revenue countries<sup>7</sup>. The Global Burden of Disease in 2019 reported that the number of death due to hepatic cirrhosis in Southeast Asia was over 442,000 making Southeast Asia the region with the biggest number of death due to hepatic cirrhosis in the world<sup>8</sup>. Hepatitis cases in Indonesia increased twofold from those in 2007 - 2013<sup>9</sup>. Hepatitis has a risk of up to 50% to become of chronic liver disease<sup>10</sup>. Besides due to chronic hepatitis virus and non-

1. Hadi Sarosa, Physiology Department of Medical Faculty, Universitas Islam Sultan Agung.
2. Wildan Chanieful Wajjih, Student of Medical Faculty, Universitas Islam Sultan Agung.
3. Ulfah Dian Indrayani, Histology Department of Medical Faculty, Universitas Islam Sultan Agung.

**Correspondence:** Hadi Sarosa, Physiology Department of Medical Faculty, Universitas Islam Sultan Agung.  
Email: [hadisarosa@unissula.ac.id](mailto:hadisarosa@unissula.ac.id)

alcoholic fatty liver disease (NAFLD), over one-third of chronic liver disease cases are caused by iron accumulation. Administration of iron sucrose at a dose of 1.5 mg intra peritoneal injection intermittently initiates fibrosis in mouse's heart <sup>11</sup>. Iron overload also triggers inflammation and apoptosis in mouse's pancreatic cells administered with 180 mg/kg of iron <sup>12</sup>.

Iron overload in the liver also affects oxidative stress with instigates excessive formation of Reactive Oxygen Species (ROS) which will cause cell death <sup>13,14</sup>. Cell death or necrosis in the liver is commonly found in the area close to central vena or zone 3 <sup>15</sup>. Hepatocyte injury led to stellate cell activation that affects fibrosis on hepatic perisinusoidal and sinusoid <sup>16</sup>. Fibrosis in the tissue is easily observed in histopathology preparation with Masson's trichrome stain <sup>17</sup>. Deferasirox has a tridentate molecule with BM 373, a half-life 8 – 16 hours which will be easily absorbed in digestive tract. Metabolism and elimination of Deferasirox take place in the form of Fe-(Dfx)2 through glucuronidase and hepatobiliary excretion to feces. Deferasirox is an iron chelation drugs with antifibrotic effect <sup>18</sup>. According to Sobbe (2015), deferasirox does not decrease fibrosis in the mouse's liver <sup>19</sup>. The result of the study is different from that of the study conducted by Adel (2019) which reported that deferasirox decreased mouse's fibrotic band <sup>18</sup>.

Based on the explanation, the effectiveness of deferasirox in preventing liver fibrosis in Balb/c mice due to iron overload need to be evaluated.

## Method

### Design

This study is post-test control group design experimental research. The transformation of hepatic histopathology was assessed by measuring fibrosis area fraction using software image J.

### Animal experiment

The subjects of the study were 8-week-old male Balb/c mice (n= 15) with a body weight of 25-40 g from the Experimental Animal Raising Unit (UPHP) LPPT Gadjah Mada University. The Balb/c mice were raised in the cage of the Biology Laboratory the faculty of Medicine, Sultan Agung Islamic University, with 12:12 hours of light-dark conditions, humidity: 50-60%, temperature: 24°-26°. The male Balb/c mice were divided into 3 groups, each n=5. Group 1 (NaCl+S) was administered with 0.3 cc Na Cl

0.9% intra peritoneal (I.P) injection and drug solvent (Aquabidest, CMC and Nipagin) 0.5 cc (P.O), group 2 (Fe+S) was administered with 1.5 mg (0.3 cc) Fe+sucrose (Venofer®) through I.P. injection and drug solvent 0.5 cc per oral (P.O)., and group 3 (Fe+Dfx) was administered with 1.5 mg (0.3 cc) Fe+sucrose (Venofer®) through I.P. injection and deferasirox 20 mg/kg BW/day through P.O. Administration of the I.P. injection was carried out intermittently. The mice were given standard feed and water *ad libitum* and they were sacrificed after 60 days of treatment.

### Liver preparation

Before being sacrificed, the mice were anesthetized with pentobarbital 60 mg/kgBW through I.P. injection. After that, their abdomens were operated on take out the liver. The liver was fixated using PFA 4% in PBS for 24 hours and the tissue was stored in A paraffin block.

### Histological Analysis

Paraffin blocks were cut into 4 mm of thickness. They were deparaffined and stained using Masson's Trichrome stain. Fibrosis area fraction was examined using *software Image J* with 5 different fields of vision in zone 2 of the liver, with a magnification of 400 X. Zone 2 liver is the zone between zone 1 which is close to theportal triad, and zone 3 which is close to A central vein.


### Statistical Analysis

The difference in fibrosis area fraction between group 2 and 3 was evaluated using Independent Sample T-test and the difference in Balb/c mice's body weight between pre-test and post-test was tested using Paired Sample T-test. The statistical analysis was carried out using the software IBM SPSS Statistics 26.

**Ethical clearance:** The research design was by the Declaration of Helsinki and was carried out upon approval of the Bioethical Commission of the Faculty of Medicine, Sultan Agung Islamic University (187/VII/2021/ Bioethics Committee).

### Result

Balb/c mice's body weight was evaluated pre and post-treatment. The highest average body weight of balb/c mice was of group 2 (Fe+S) compared to that of group 3 (Fe+Dfx) and group 1 (NaCl+S). The mice had significantly different body weights (p<0.05) pre and post-treatment (see table 1). The balb/c mice's body weight was kept between 25-40g as per inclusion criteria.



**Figure 1** Representative figure of liver fibrosis area shown by Masson’s Trichrome staining. Group 1 demonstrated normal liver without fibrosis area. Blue color confirmed deposition of thick collagen fiber in group 2 and deposition of fine collagen fiber in group 3.

**Table 1.** Balb/c mice’s average body weight (gram) of various treatment groups

Mice	Average Body Weight (g)		p-value
	Pre-Test	Post-Test	
Group 1 (NaCl+S)	27.9 ± 0.8	30.7 ± 3.6	0.00*
Group 2 (Fe+S)	24.8 ± 1.8	31.4 ± 3.7	0.00*
Group 3 (Fe+Dfx)	27.4 ± 1.3	31.8 ± 3.6	0.00*

\* p<0.05 significantly different based on Paired Sample T-Test

The fibrosis area fraction in the liver was observed in zone 2 in avoidance of bias from damage commonly occurring in zone 3 because of acute hypoxia during the sacrifice process. Fibrosis was not found in the mice’s liver in group 1 (NaCl + S), the group without Fe sucrose administration (see figure 1).

Deferasirox administration for mice with iron overload may reduce liver fibrosis area fraction. Fe sucrose administration of 1.5 mg through I.P. injection intermittently may trigger the formation of liver fibrosis. Fibrosis area fraction adequately occurred within group 2 (Fe+S) was higher than that of group 3 (Fe+Dfx). There is a significant difference (p<0.05) in fibrosis area fraction between group 2 (Fe+S) and group 3 (Fe+Dfx) (see table 2).

**Table 2.** Percentage of Fibrosis Area Fraction in Various Groups of Balb/c Mice

Group	Mean± Standard Deviation	p value
Group 2 (Fe + S)	9.17±8.54	0.000*
Group 3 (Fe + Dfx)	1.38±0.20	

\* p<0.05 significantly different based on Independent Sample T-Test

### Discussion

The liver has perisinusoidal space as the place for substance exchange from blood in the sinusoid to basolateral hepatocyte. The stellate cell that is located in the perisinusoidal space serves to help remodel hepatocyte and sinusoid epithelium. The stellate cell produces hepatocyte growth factor (HGF) to initiate hepatocyte regeneration and secrete collagen that composes fibrosis in the liver. Transforming growth factor β (TGF β) is cytokine that will induce fibrosis by synthesizing extracellular matrix components, namely collagen types I and III, α-SMA, laminin and fibronectin<sup>16</sup>. Other fibrotic collagens are II, IV, XI, XXIV and XXVII. This fibrosis is the scaffold for hepatocytes to proliferate<sup>20</sup>.

In this study, fibrosis was not found in mice without iron administration since physiologically iron deposition (hemosiderin)<sup>21</sup> and fibrosis<sup>22</sup> do not occur in the liver. Iron in hepatocyte is stored in ferritin and free iron in cells will partially be used by mitochondria<sup>14</sup>. Extra iron causes the formation of hemosiderin iron<sup>23</sup>. Electron charge of Fe<sup>2+</sup> and Fe<sup>3+</sup> in hemosiderin may be stained blue using Prussian blue staining<sup>24</sup>. Fibrosis in the liver will be formed due to hepatocyte damage<sup>20</sup>. Liver damage occurs due to increased Reactive Oxygen Species (ROS)<sup>25</sup> caused by the increase of labile plasma iron (LCI)<sup>14</sup>. LCI content in the liver is kept at about 0.5 – 1.5 μM in normal conditions<sup>26</sup>.



Administration of iron sucrose 1.5 mg through I.P. injection intermittently causes liver fibrosis. Iron overload causes hepatocyte and kupffer cells to produce TGF $\beta$ <sup>27</sup>. Transforming growth factor $\beta$  (TGF $\beta$ ) causes lipid hepatocyte peroxidation and activates stellate cells to produce collagen<sup>27</sup> and fibrosis formation in perisinusoidal space<sup>28</sup>. The research conducted by Sangartit (2016) explained that iron sucrose through I.P. injection increased iron serum, ferritin, transferrin saturation (TfSat), and Non transferrin bound iron (NTBI) level<sup>29</sup>. Iron sucrose administration through I.P injection increased TGF $\beta$  level and fibrosis in the heart<sup>11</sup>. Oral administration of iron supplement (FeSO<sub>4</sub>) did not increase NTBI level<sup>30</sup>. It takes time for absorption of oral iron administration compared to parenteral administration since iron is absorbed in the intestine only 1-2 mg/day equal to the body's iron excretion<sup>31</sup>. Intraperitoneal administration increases iron levels in the liver and heart<sup>32</sup> since it does not pass iron regulation in the intestine<sup>33</sup>.

Deferasirox (Dfx) administration inhibits fibrosis growth in Balb/c mice's liver in this research. This result is coherent with previous study. Dfx has significant hepatoprotective and antifibrotic roles through inhibition of inflammatory processes in the liver<sup>18</sup>. Dfx administration in iron therapy can prevent proinflammatory activity by inhibiting tumor necrosis factor alpha (TNF $\alpha$ )<sup>34</sup>. Dfx is antifibrotic since it can suppress signals from TGF $\beta$  in mice with extra iron<sup>35</sup>. Dfx is also an antioxidant<sup>18</sup> thus it can prevent apoptosis of hepatocytes<sup>36</sup>. Decreased collagen deposition in the liver of mice with extra iron occurs with the group of Wistar rats administered with Dfx<sup>37</sup>. In clinical practice, Dfx is an important iron chelation management for patient with thalassemia and secondary iron overload<sup>38</sup>.

Liver damage occurs with the administration of ferumoxytol (FMX) and low molecular weight iron dextran (LMWID) through IV but the damage does not occur with the administration of iron sucrose (IS) and ferric carboxymaltose (FCM)<sup>39</sup>. Meanwhile, according to Ito (2016), parenteral administration of iron sucrose may increase NTBI<sup>40</sup>. Sodium ferric gluconate (SFG), compared with IS, shows higher

retention of iron<sup>41</sup>. The lower weight of SFG (37.5 kDa) and IS (43 kDa) molecules may increase NTBI and LPI higher than FCM (150 kDa), iron dextran (103 kDa), and FMX (185 kDa)<sup>42</sup>. Each type of iron therapy has a different capability to increase iron serum in the body.

Iron sucrose can be administered intraperitoneally for extra iron tests in mice<sup>11,32</sup>. Mice administered with IS 50 mg/kg intraperitoneally 2 times a week increased iron deposit in the liver, lien, and bone marrow<sup>43</sup>. Mice administered with IS intraperitoneally for 4 weeks with a low dose (5 mg/mL) did not show any pathological change in the liver's structure, the damage started occurring and there was minimum iron deposit with a medium dose (10 mg/mL). Meanwhile a high dose of iron sucrose (20 mg/mL) showed strong damage to liver structure with the thick brown iron deposit in hepatocyte<sup>44</sup>. Therefore, it is necessary to consider using a variety of doses of iron sucrose to trigger iron overload within the liver.

Liver damage is not only caused by the increase of NTBI/LPI<sup>45</sup>. Toxicity of tissue iron is directly proportional to tissue reactive species (NTBI/LPI), genetics, environment, and duration of exposure<sup>14</sup>. Liver fibrosis can also be reduced with stellate cell apoptosis processed by NK cells<sup>46</sup>. NK cell produces INF $\gamma$  with an antifibrogenic effect through inhibiting TGF $\beta$  signaling, thus stellate cell cannot be activated<sup>46,47</sup>. Fibrosis in the liver, lung, and lien is marked with TGF $\beta$  level increase<sup>48</sup>. Hepcidin administration for mice reduces TGF $\beta$  levels<sup>49</sup>. Bone Morphogenetic Protein 6 (BMP6) and Bone Morphogenetic Protein Receptor (BMPR) will increase hepcidin expression when iron count or load increases<sup>50</sup>. Hepcidin prevents ferroportin releases iron from enterocytes to blood circulation<sup>14</sup>. Hepcidin can also directly protect liver from fibrosis by deactivating stellate cells in the perisinusoidal space in the liver<sup>51</sup>. Hepcidin level recovery may prevent fibrosis by preventing activation of stellate cell<sup>52</sup>.

This study did not use other iron chelating drugs; deferasirox only; since deferasirox has a long half-life effect (t<sub>1/2</sub>, 11–19 hours) making it possible to be administered as once-daily oral regimen. This study is limited in that the dose of deferasirox did

not vary, thus the authors cannot explain the dose of deferasirox that inhibits liver fibrosis. In addition, this study did not evaluate iron levels in the blood.

### Conclusion

Intermittently intraperitoneal injection of iron sucrose may cause liver fibrosis in Balb/c mice. Deferasirox administration decreases the percentage of mice's fibrosis area fraction induced by iron sucrose.

### Acknowledgment

The authors wish to thank the Faculty of Medicine, Universitas Islam Sultan Agung for funding this study.

### Conflict of interest

The researcher has no conflict of interest in this publication.

### Authors' Contribution:

Idea owner of this study: Hadi Sarosa

Study design: Hadi Sarosa

Data gathering: Ulfah Dian Indrayani, Wildan Chanieful Wajjih

Writing and submission of manuscript: Hadi Sarosa, Ulfah Dian Indrayani, Wildan Chanieful Wajjih

Editing and approval of final draft: Hadi Sarosa, Ulfah Dian Indrayani

---

### References

1. Kang H, Han M, Xue J, Baek Y, Chang JO, Hu S, et al. Renal clearable nanochelators for iron overload therapy. *Nature Communications*. 2019;10(1).
2. Kang H, Han M, Xue J, Baek Y, Chang JO, Hu S, et al. Renal clearable nanochelators for iron overload therapy. *Nature Communications*. 2019;10(1):1–11.
3. Wahidiyat PA, Liauw F, Sekarsari D, Putriasih SA, Berdoukas V, Pennell DJ. Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2\* magnetic resonance imaging. *Hematology*. 2017;22(8):501–7.
4. Ghosh, Som; ChakrBrti D. Estimation of serum ferritin and TSH levels in thalassemia patients undergoing iron chelation therapy. *Bangladesh Journal of Medical Science*. 2021;20(01):130–5.
5. Kühn JP, Meffert P, Heske C, Kromrey ML, Schmidt CO, Mensel B, et al. Prevalence of fatty liver disease and hepatic iron overload in a northeastern German population by using quantitative MR imaging. *Radiology*. 2017;284(3):706–16.
6. Duarte TL, Caldas C, Santos AG, Silva-Gomes S, Santos-Gonçalves A, Martins MJ, et al. Genetic disruption of NRF2 promotes the development of necroinflammation

- and liver fibrosis in a mouse model of HFE-hereditary hemochromatosis. *Redox Biology*. 2017;**11**(November 2016):157–69.
7. World Health Statistics 2021: Monitoring Health for The SDGs, Sustainable Development Goals. Geneva: World Health Organization; 2021.
  8. Abbafati C, Machado DB, Cislighi B, Salman OM, Karanikolos M, McKee M, et al. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *The Lancet*. 2020;**396**(10258):1160–203.
  9. Riskesdas. Riset KESEHATAN DASAR (RISKESDAS) 2013. Laporan Nasional 2013. Jakarta; 2013. p. 1–306.
  10. Kemenkes RI. Situasi dan Analisis Hepatitis di Indonesia. *PusdatinKemenkes RI*. Jakarta; 2014. p. 1–8.
  11. Sarosa H, Bahrudin U, Soemantri A, Fatimah-muis S, Arfian N, Hisatome I. The Protective Effect of Azelnidipine for the Prevention of Heart Fibrosis Occurrence on Balb/c Mice with Iron Overload. *Bangladesh Journal of Medical Science*. 2020;**19**(02):223–8.
  12. Chen M, Zheng J, Liu G, Xu E, Wang J, Fuqua BK, et al. Ceruloplasmin and hephaestin jointly protect the exocrine pancreas against oxidative damage by facilitating iron efflux. *Redox Biology*. 2018;**17**(May):432–9.
  13. Güvendi GF, Eroğlu HA, Mustafa Makav, Güvendi B, Adalı Y. Selenium or ozone: Effects on liver injury caused by experimental iron overload. *Life Sciences*. 2020 Dec;**262**:118558.
  14. Pilo F, Angelucci E. Iron toxicity and hemopoietic cell transplantation: Time to change the paradigm. *Mediterranean Journal of Hematology and Infectious Diseases*. 2019;**11**(1):1–8.
  15. Assis-Mendonça GR, Cunha-Silva M, Fernandes MF, Torres LD, De Almeida Verissimo MP, Okano MTN, et al. Massive iron overload and acute-on-chronic liver failure in a patient with Diamond-Blackfan anaemia: A case report. *BMC Gastroenterology*. 2020;**20**(1):1–7.
  16. Parola M, Pinzani M. Molecular Aspects of Medicine Liver fibrosis : Pathophysiology , pathogenetic targets and clinical issues. *Molecular Aspects of Medicine*. 2019;**65**:37–55.
  17. Kaimori JY, Isaka Y, Hatanaka M, Yamamoto S, Ichimaru N, Fujikawa A, et al. Diffusion Tensor Imaging MRI With Spin-Echo Sequence and Long-Duration Measurement for Evaluation of Renal Fibrosis in a Rat Fibrosis Model. *Transplantation Proceedings*. 2017;**49**(1):145–52.
  18. Adel N, Mantawy EM, El-Sherbiny DA, El-Demerdash E. Iron chelation by deferasirox confers protection against concanavalin A-induced liver fibrosis: A mechanistic approach. *Toxicology and Applied Pharmacology*. 2019;**382**(September):114748.
  19. Sobbe A, Bridle KR, Jaskowski L, de Guzman CE, Santrampurwala N, Clouston AD, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. *Journal of Gastroenterology and Hepatology (Australia)*. 2015;**30**(3):638–45.
  20. Ruoß M, Rebholz S, Weimer M, Grom-baumgarten C, Athanasopulu K, Kemkemer R, et al. Development of Scaffolds with Adjusted Stiffness for Mimicking Disease-Related Alterations of Liver Rigidity. *J Funct Biomater*. 2020;**11**(1):17.
  21. Zhabyeyev P, Das SK, Basu R, Shen M, Patel VB, Kassiri Z, et al. TIMP3 deficiency exacerbates iron overload-mediated cardiomyopathy and liver disease. 2021;978–90.
  22. Iwaisako K, Brenner DA, Kisseleva T. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. *Journal of Gastroenterology and Hepatology (Australia)*. 2012;**27**(SUPPL.2):65–8.
  23. Golfeyz S, Lewis S, Weisberg IS. Hemochromatosis: pathophysiology, evaluation, and management of hepatic iron overload with a focus on MRI. *Expert Review of Gastroenterology and Hepatology*. 2018;**12**(8):767–78.
  24. Grandjean F, Samain L, Long GJ. Characterization and utilization of Prussian blue and its pigments. *Dalton Transactions*. 2016;**45**(45):18018–44.
  25. Abbina S, Abbasi U, Gill A, Wong K, Kalathottukaren MT, Kizhakkedathu JN. Design of Safe Nanotherapeutics for the Excretion of Excess Systemic Toxic Iron. *ACS Central Science*. 2019;**5**(5):917–26.
  26. Cabantchik ZI. Labile iron in cells and body fluids : physiology , pathology , and pharmacology. 2015;(June).
  27. Yoon IC, Eun JR. Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology. *Yeungnam University Journal of Medicine*. 2019;**36**(2):67–77.
  28. Cordero-Espinoza L, Huch M. The balancing act of the liver: tissue regeneration versus fibrosis. *Journal of Clinical Investigation*. 2018;**128**(1):85–96.
  29. Sangartit W, Pakdeechote P, Kukongviriyapan V, Donpunha W, Shibahara S, Kukongviriyapan U. Tetrahydrocurcumin in combination with deferiprone attenuates hypertension, vascular dysfunction, baroreflex dysfunction, and oxidative stress in iron-overloaded mice. *Vascular Pharmacology*. 2016;**87**:199–208.
  30. Steele SL, Kroeun H, Karakochuk CD. The effect of daily iron supplementation with 60 mg ferrous sulfate for 12

- weeks on non-transferrin bound iron concentrations in women with a high prevalence of hemoglobinopathies. *Journal of Clinical Medicine*. 2019;**8**(2).
31. Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. *International Journal of Hematology*. 2018;**107**(1):16–30.
  32. Italia K, Colah R, Ghosh K. Experimental animal model to study iron overload and iron chelation and review of other such models. *Blood Cells, Molecules, and Diseases*. 2015;**55**(3):194–9.
  33. Stefanova D, Raychev A, Arezes J, Ruchala P, Gabayan V, Skurnik M, et al. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron. *Blood*. 2017;**130**(3):245–57.
  34. Banerjee A, Mifsud NA, Bird R, Forsyth C, Szer J, Tam C, et al. The oral iron chelator deferasirox inhibits NF- $\kappa$ B mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia. *British Journal of Haematology*. 2015 Feb;**168**(4):576–82.
  35. Zhang Y, Zhang Y, Xie Y, Gao Y, Ma J, Yuan J, et al. Multitargeted inhibition of hepatic fibrosis in chronic iron-overloaded mice by *Salvia miltiorrhiza*. *Journal of Ethnopharmacology*. 2013 Jul;**148**(2):671–81.
  36. Isidori A, Borin L, Elli E, Latagliata R, Martino B, Palumbo G, et al. Iron toxicity – Its effect on the bone marrow. Vol. 32, Blood Reviews. *Elsevier Ltd*; 2018. 473–479 p.
  37. Rahdar A, Hajinezhad MR, Sargazi S, Bilal M, Barani M, Karimi P, et al. Biochemical effects of deferasirox and deferasirox-loaded nanomicelles in iron-intoxicated rats. *Life Sciences*. 2021;270(February):119146.
  38. Bollig C, Lk S, Rücker G, Allert R, Motschall E, Cm N, et al. Deferasirox for managing iron overload in people with thalassaemia (Review). 2017;
  39. Toblli JE, Cao G, Giani JF, Dominici FP, Angerosa M. Nitrosative Stress and Apoptosis by Intravenous Ferumoxytol, Iron Isomaltoside 1000, Iron Dextran, Iron Sucrose, and Ferric Carboxymaltose in a Nonclinical Model. *Drug Research*. 2014;**65**(7):354–60.
  40. Ito S, Ikuta K, Kato D, Lynda A, Shibusa K, Niizeki N, et al. In vivo behavior of NTBI revealed by automated quantification system. *International Journal of Hematology*. 2016;**104**(2):175–81.
  41. Span K, Pieters EHE, Brinks V, Hennink WE, Schellekens H. Evaluation of the suitability of a Sprague Dawley rat model to assess intravenous iron preparations. *Journal of Pharmacological and Toxicological Methods*. 2018;**91**:7–17.
  42. Bhandari S, Pereira DIA, Chappell HF, Drakesmith H. Intravenous irons: From basic science to clinical practice. *Pharmaceuticals*. 2018;**11**(3):1–20.
  43. Abedi M, Rahgozar S, Esmaili A. Iron protects childhood acute lymphoblastic leukemia cells from methotrexate cytotoxicity. *Cancer Medicine*. 2020;**9**(10):3537–50.
  44. Wu XQ, Lin KN, Chen MM, Jiang PF, Zhang YX, Chen YQ, et al. Iron overload as a risk factor for poor graft function following allogeneic hematopoietic stem cell transplantation. *Kaohsiung Journal of Medical Sciences*. 2020;**36**(10):825–33.
  45. Liu D, He H, Yin D, Que A, Tang L, Liao Z, et al. Mechanism of chronic dietary iron overload induced liver damage in mice. *Molecular Medicine Reports*. 2013;**7**(4):1173–9.
  46. Hou X, Yu F, Man S, Huang D, Zhang Y, Liu M, et al. Negative regulation of *Schistosoma japonicum* egg-induced liver fibrosis by natural killer cells. *PLoS Neglected Tropical Diseases*. 2012;**6**(1):1–10.
  47. Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM, et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. *Hepatology*. 1996;**23**(5):1189–99.
  48. Hu HH, Chen DQ, Wang YN, Feng YL, Cao G, Vaziri ND, et al. New insights into TGF- $\beta$ /Smad signaling in tissue fibrosis. *Chemico-Biological Interactions*. 2018;**292**:76–83.
  49. Liu WY, Wang L, Lai YF. Hepcidin protects pulmonary artery hypertension in rats by activating NF- $\kappa$ B/TNF- $\alpha$  pathway. *European Review for Medical and Pharmacological Sciences*. 2019;**23**(17):7573–81.
  50. Cells RED, Canali S, Zumbrennen-bullough KB, Core AB, Wang C yu, Nairz M, et al. Plenary Paper Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. 2017;**129**(4):405–14.
  51. Vela D. Low hepcidin in liver fibrosis and cirrhosis ;a tale of progressive disorder and a case for a new biochemical marker. 2018;1–18.
  52. Han CY, Koo JH, Kim SH, Gardenghi S, Rivella S, Strnad P, et al. Hepcidin inhibits Smad3 phosphorylation in hepatic stellate cells by impeding ferroportin-mediated regulation of Akt. *Nature Communications*. 2016;**7**(May):1–14.